CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
with HER2-positive gastric or gastro-esophageal junction (GEJ) adenocarcinoma who have progressed on or after a trastuzumab-containing regim...
Phase 3
Taipei, Taiwan and 157 other locations
and immunogenicity of novel combination therapies in participants with locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma...
Phase 2
Taipei, Taiwan and 42 other locations
and placebo in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC).This study aims to explore whether blockade of Transforming Gr...
Phase 3
Taipei, Taiwan and 113 other locations
The purpose of this study is to evaluate the efficacy of zolbetuximab plus capecitabine and oxaliplatin (CAPOX) compared with placebo plus CAPOX (as...
Phase 3
Taipei, Taiwan and 164 other locations
of Evorpacept (ALX148) in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Patients With Advanced HER2-overexpressing gastric/GEJ adenocarcinoma...
Phase 2, Phase 3
Taipei, Taiwan and 54 other locations
The purpose of this study is to confirm the recommended phase 2 dose (RP2D) of zolbetuximab in combination with Nab-P + GEM, determine overall surviv...
Phase 2
Taipei City, Taiwan and 137 other locations
chemotherapy with leucovorin, oxaliplatin, docetaxel and S-1 (LOTS) in patients with locally advanced gastric or gastroesophageal junction adenocarcinoma...
Phase 2
Taipei, Taiwan and 3 other locations
and safety of AZD0901 compared to Investigator's choice of therapy as 2L+ treatment for participants with advanced or metastatic gastric or GEJ adenocarcinoma...
Phase 3
Taipei, Taiwan and 157 other locations
generating, open-label, 2-Arm, non-randomized study, in patients with metastatic HER2/neu over-expressing gastric cancer or gastroesophageal adenocarcinomas...
Phase 2
Taipei, Taiwan and 6 other locations
The Phase 1b study is an open-label, multicenter dose escalation study designed to assess the safety, tolerability, immunogenicity and recommended ph...
Phase 1, Phase 2
Taipei, Taiwan and 21 other locations
Clinical trials
Research sites
Resources
Legal